Azelnidipine, a new dihydropyridine calcium ion antagonist, was protected by patent in
Japan. In present study, identifications of the crystal phases, including two polymorphic and …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
37101528&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

A new high performance liquid chromatography method was developed and validated for
the quantitation of Cilnidipine and Valsartan in pharmaceutical formulations. Determination …

Candesartan cilexetil is a pharmacological compound belonging to the class of angiotensin
II receptor blockers (ARBs), which are widely used in the management of cardiovascular …

The purpose of this study was to evaluate the efficacy and safety of cilnidipine tablets to treat
Chinese patients with mild to moderate essential hypertension, and to examine the ability of …

Azelnidipine (CS-905) is a long-acting, once-daily, orally-administered calcium channel
antagonist which is being jointly developed by Sankyo and UBE. An NDA for the treatment of …

Background-The chase to improve the quality of life has stimulated desirable changes in
research to design and develop a new drug and enhance its safety and effectiveness. Thus …

新型钙离子拮抗剂尼伐地平-[维普官方网站]-www.cqvip.com-维普网  我的维普 购物车 充值 客服
首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术机构 您的 …